Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib PK and Safety in Renal Impairment
NCT02199379Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in thyroid cancer, renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Zero to Infinity and 1 more. Started Nov 2011; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02199379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199379.